计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| N414283-1mg |
1mg |
现货 ![]() |
| |
| N414283-5mg |
5mg |
现货 ![]() |
| |
| N414283-10mg |
10mg |
现货 ![]() |
| |
| N414283-25mg |
25mg |
现货 ![]() |
| |
| N414283-50mg |
50mg |
现货 ![]() |
|
| 英文别名 | (R)-6-(3-((3-Hydroxy-1-methyl-2-oxopyrrolidin-3-yl)-ethynyl)phenyl)-4-methoxypicolinamide, 6-[3-[2-[(3R)-3-Hydroxy-1-methyl-2-oxo-3-pyrrolidinyl]ethynyl]phenyl]-4-methoxy-2-pyridinecarboxamide, NIK small molecule inhibitor 1 |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | NIK SMI1 |
| 生化机理 | NIK SMI1 是一种高活性、高选择性的 NF-κB 诱导激酶(NIK)抑制剂,在 NIK 催化的 ATP 向 ADP 的水解过程中,其 Ki 为 0.23 nM。6/75.2/247.8 nM),可选择性地破坏非正则 NF-κB 信号转导(抗 LTβR 诱导的 p52 核转位 IC50 = 70 nM;TNFα 诱导的 p65 RelA 核转位 IC50 >2 μM)。SMI1 可抑制培养物(人和小鼠 B 细胞)中 BAFF 受体和 CD40 介导的单细胞聚集,并在 NZB/W F1 小鼠实验性狼疮模型中显示出体内疗效(6-400 毫克/千克/天,口服)。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 富亮氨酸重复激酶 2 抑制剂;丝裂原活化蛋白激酶激酶 14 抑制剂;丝裂原活化蛋白激酶激酶 5 抑制剂;蛋白激酶 D1 抑制剂 |
| 产品介绍 |
Information NIK SMI1 NIK SMI1 is a highly potent and selective NF-κB-inducing kinase (NIK) inhibitor with Ki of 0.23 nM for NIK-catalyzed hydrolysis of ATP to ADP. Targets NIK-catalyzed hydrolysis of ATP to ADP 0.23 nM(Ki) In vitro NIK SMI1 exhibits selective inhibition of LTβR-dependent p52 translocation and transcription of NF-κB2 related genes. NIK SMI1 is shown to have a favorable pharmacokinetic profile across species and to inhibit BAFF-induced B cell survival in vitro. In vivo NIK SMI1 inhibits BAFF signaling and reduces splenic marginal zone B cells in vivo. Cell Research(from reference) Cell lines:293 cells, HeLa cells, SF9 cell line, Human B cells, Mouse B cells Concentrations:1 μM, different concentrations Incubation Time:24 h, 5 h |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IUPAC Name | 6-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl]-4-methoxypyridine-2-carboxamide |
| INCHI | InChI=1S/C20H19N3O4/c1-23-9-8-20(26,19(23)25)7-6-13-4-3-5-14(10-13)16-11-15(27-2)12-17(22-16)18(21)24/h3-5,10-12,26H,8-9H2,1-2H3,(H2,21,24)/t20-/m0/s1 |
| InChi Key | LQSHXYHWYGKAMX-FQEVSTJZSA-N |
| Canonical SMILES | CN1CCC(C1=O)(C#CC2=CC(=CC=C2)C3=NC(=CC(=C3)OC)C(=O)N)O |
| Isomeric SMILES | CN1CC[C@](C1=O)(C#CC2=CC(=CC=C2)C3=NC(=CC(=C3)OC)C(=O)N)O |
| PubChem CID | 117902000 |
| 分子量 | 365.38 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 73 mg/mL (199.79 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| 分子量 | 365.400 g/mol |
| XLogP3 | 0.900 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 365.138 Da |
| 单同位素质量Monoisotopic Mass | 365.138 Da |
| 拓扑极表面积Topological Polar Surface Area | 106.000 Ų |
| 重原子数Heavy Atom Count | 27 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 654.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC area) | |
|---|---|
| Enantiomeric Excess | |
| LC-MS for identification | Conforms |
| Proton NMR spectrum | Conforms to Structure |
¥3,999.90
| 1. Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S et al.. (2018) NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.. Nat Commun, 9 (1): (179). [PMID:29330524] |